quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:00:00·35d
PRRelease
Collegium Pharmaceutical Inc. logo

Collegium to Acquire AZSTARYS® from Corium Therapeutics, Strengthening Position in ADHD and Accelerating Growth Trajectory

COLL· Collegium Pharmaceutical Inc.
Health Care
Original source

Companies

  • COLL
    Collegium Pharmaceutical Inc.
    Health Care

Recent analyst ratings

  • Dec 9UpdateBarclays$58.00
  • Jan 10UpdateNeedham$46.00
  • Jul 30UpdateH.C. Wainwright$47.00
  • Jun 7UpdateJefferies$44.00
  • May 10UpdateNeedham-
  • May 10UpdatePiper Sandler$39.00

Related

  • PR19h
    Collegium to Report First Quarter 2026 Financial Results on May 7, 2026
  • PR15d
    Collegium to Participate in Upcoming Investor Conferences
  • SEC16d
    SEC Form DEF 14A filed by Collegium Pharmaceutical Inc.
  • SEC16d
    Collegium Pharmaceutical Inc. filed SEC Form 8-K: Leadership Update
  • INSIDER20d
    SEC Form 4 filed by Dieter David
  • SEC28d
    Amendment: SEC Form SCHEDULE 13G/A filed by Collegium Pharmaceutical Inc.
  • INSIDER34d
    SEC Form 4 filed by Dieter David
  • SEC35d
    Collegium Pharmaceutical Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022